Hua Ling Pharmaceuticals submitted a new Securities Variation Monthly Report on September 30, 2024, reporting that the company's statutory/registered capital and issued shares remained unchanged this month, staying at $2,000,000,000 and 1,055,588,761 shares. In addition, there were no new stock options issued or exercised under the company's stock options plan, and the remaining number of stock options stood at 52,799,265 shares. The report was submitted by company secretary Yuan Yingxin on October 7, 2024, confirming that all securities issuances or inventory share sales or transfers have been authorized by the board of directors and comply with relevant listing rules and legal regulations.

Hua Ling Pharmaceuticals submitted a new Securities Variation Monthly Report on September 30, 2024, reporting that the company's statutory/registered capital and issued shares remained unchanged this month, staying at $2,000,000,000 and 1,055,588,761 shares. In addition, there were no new stock options issued or exercised under the company's stock options plan, and the remaining number of stock options stood at 52,799,265 shares. The report was submitted by company secretary Yuan Yingxin on October 7, 2024, confirming that all securities issuances or inventory share sales or transfers have been authorized by the board of directors and comply with relevant listing rules and legal regulations.